tiprankstipranks
Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Relay Therapeutics (RLAY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTXResearch Report) and Relay Therapeutics (RLAYResearch Report).

BioNTech SE (BNTX)

In a report released today, Akash Tewari from Jefferies maintained a Hold rating on BioNTech SE, with a price target of $230.00. The company’s shares closed last Monday at $141.00, close to its 52-week low of $121.32.

According to TipRanks.com, Tewari is a 4-star analyst with an average return of 16.1% and a 44.4% success rate. Tewari covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, BioMarin Pharmaceutical, and Enanta Pharmaceuticals.

BioNTech SE has an analyst consensus of Moderate Buy, with a price target consensus of $251.89.

See today’s best-performing stocks on TipRanks >>

Relay Therapeutics (RLAY)

In a report released today, Gaurav Goparaju from Berenberg Bank maintained a Buy rating on Relay Therapeutics, with a price target of $45.00. The company’s shares closed last Monday at $19.51, close to its 52-week low of $19.05.

According to TipRanks.com, Goparaju is ranked #7654 out of 7878 analysts.

Relay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $45.00, representing a 124.6% upside. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $35.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BNTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed